How could real-time clinical trials speed drugs?

FDA push for “smarter” clinical trials

FDA Commissioner comments highlighted a structural bottleneck in drug development: the long “dead time” between key trial steps, and the historically slow process of getting usable evidence into regulatory decisions.

In traditional development, trials often rely on schedules that don’t allow frequent learning during the study, meaning sponsors may wait years for endpoints to mature before they can adjust strategies or confirm effectiveness. That approach can prolong the path to market—described as taking about a decade on average.

The commissioner’s emphasis on real-time clinical trials frames a shift toward studies that can generate actionable information sooner. If trial designs and data systems can support continuous or frequent monitoring—so that safety signals and signals of effectiveness can be assessed while the study is underway—then programs may be able to:

• Reduce downtime between trial phases by generating evidence earlier.
• Adapt more quickly based on accumulating data rather than waiting for endpoints to complete.
• Improve efficiency so that regulators can evaluate evidence with less delay.

The stakes are practical: faster and more efficient trials could mean patients see new therapies sooner, while also potentially lowering development costs that are ultimately reflected in drug prices.

The core message is not that trials would be eliminated, but that their pacing and evidence flow could be modernized—using smarter designs and more continuous data handling—so the development pipeline stops spending so much time “waiting for answers” to finish maturing.